Fact Checks Challenge Ramaswamy Ads Against Amy Acton in Ohio

Campaign advertising in Ohio's gubernatorial race has drawn scrutiny over claims about Democratic candidate Amy Acton's proposed spending and Republican candidate Vivek Ramaswamy's pharmaceutical record. Fact checks published by cleveland.com on October 8 and October 9, 2026, challenged statements in Ramaswamy's advertisements, while a separate analysis highlighted disputed claims by a political action committee supporting his candidacy.

A central dispute concerns a Republican advertisement claiming that an Acton administration would increase state spending by $21 billion and double Ohio's income taxes. According to cleveland.com, Acton has not proposed either an expenditure plan with that price tag or an income-tax increase.

The publication classified both claims as lies under its fact-checking standard because the advertisement did not support them with evidence from the cited sources. The $21 billion figure instead reflects Republican estimates based on assumptions about policies Acton has not proposed.

Acton's Affordability Plan includes medical-debt relief, expanded tax credits for children and lower-income families, lower prescription-drug costs, and measures addressing health care and energy expenses. Her campaign has also proposed closing tax loopholes that benefit wealthy Ohioans, but it has not published a comprehensive cost estimate for the plan.

The advertisement cites North Columbus News, which referenced an X post by Republican state Rep. Brian Stewart promoting the spending claim. Cleveland.com said its earlier reporting had already examined the calculation and found that it relied on assumptions about Acton's agenda rather than an established spending proposal.

A separate cleveland.com fact check published October 8 examined a Ramaswamy campaign advertisement defending his pharmaceutical record. The advertisement featured a prostate-cancer patient criticizing Acton's account of Ramaswamy's unsuccessful effort to develop intepirdine, an experimental Alzheimer's drug.

The publication challenged three claims in the advertisement, including the suggestion that pharmaceutical companies had overlooked a promising prostate-cancer treatment before Ramaswamy intervened. The drug in question was not identified in the advertisement, but the reporting indicated that the patient was likely referring to relugolix.

According to cleveland.com, Takeda Pharmaceutical Company had already tested relugolix in Phase 2 clinical trials before licensing it to Myovant Sciences, a company established in partnership with Ramaswamy's Roivant Sciences. Takeda had described the treatment as promising, contradicting the advertisement's implication that pharmaceutical companies had passed over the drug.

Roivant contributed to relugolix's development through Myovant before transferring its entire ownership interest to Sumitomo in 2019. The Food and Drug Administration approved the drug, marketed as Orgovyx, for advanced prostate cancer in 2020, and it became available in the United States the following year.

The pharmaceutical advertisement responded to Acton's criticism of Ramaswamy's record involving intepirdine. The cleveland.com analysis concluded that the patient's experience with a different medication did not establish that Acton had misrepresented the history of the Alzheimer's drug.

The dispute has also extended to advertising by V-PAC, a super PAC supporting Ramaswamy. In an analysis published October 7, 2026, the Democratic Governors Association cited a Popular Information investigation that challenged statements in a V-PAC mailer about Acton's medical license and professional competence.

The investigation found that the State Medical Board of Ohio had not called Acton incompetent. It also cited a residency adviser who described her medical knowledge as excellent. The Democratic Governors Association said a V-PAC spokesperson did not respond to a request for comment on other disputed statements in the mailer.

The Acton campaign separately challenged an advertisement featuring Dr. Alice Epitropoulos. In a statement published October 3, 2026, the campaign said Ramaswamy and his allies had spent more than $84 million on attack advertisements and questioned the doctor's political connections.

The campaign stated that Epitropoulos was Ramaswamy's direct neighbor, had appeared in a 2014 campaign advertisement for Governor John Kasich, and had donated $5,000 to Ramaswamy's campaign in 2026. These details were presented by Acton's campaign as context for assessing the advertisement's claims.

Addie Bullock, a spokeswoman for Acton's campaign, said Ramaswamy's advertisements had repeatedly misrepresented Acton's record. The campaign also disputed the description of Acton as a career politician, noting that she had never held elected office and had spent approximately three decades working as a doctor and public health expert.

The Acton campaign further cited support from more than 1,000 Ohio doctors and an endorsement from the Ohio Nurses Association, which represents more than 10,000 nurses and health professionals. According to the campaign, Acton has held a medical license since 1994.